Displaying drugs 1476 - 1500 of 1988 in total
FP0011
FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease). It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.
Investigational
PF-06282999
Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects).
Investigational
PF-03882845
PF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type 2 Diabetic Nephropathy.
Investigational
PF-04958242
PF-04958242 has been used in trials studying the basic science and treatment of Schizophrenia and Hearing Loss, Sensorineural.
Investigational
PF-00610355
PF-00610355 has been used in trials studying the treatment of Lung Disease, Moxifloxacin, Pulmonary Disease, Asthma, Bronchial, and Bronchial Diseases, among others.
Investigational
PF-04447943
PF-04447943 has been investigated for the treatment of Alzheimer's Disease.
Investigational
PF-04691502
PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast Cancer (Phase 2), and Advanced Breast Cancer (Phase 1b).
Investigational
PF-03635659
Pf03635659 has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.
Investigational
PF-06821497
PF-06821497 is under investigation in clinical trial NCT03460977 (PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma).
Investigational
PF-05089771
PF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee).
Investigational
PF-04937319
PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
Investigational
PF-06751979
PF-06751979 is under investigation in clinical trial NCT03126721 (The Study is to Evaluate the Effect of Multiple Doses PF-06751979 on the Pharmacokinetics of Midazolam in Healthy Adults).
Investigational
PF-05241328
PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity).
Investigational
PF-06650833
PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).
Investigational
CK0802
CK0802 is an off-the-shelf product composed of allogeneic umbilical cord blood derived regulatory T-cells (T-Reg cells), which can be used intravenously and without HLA matching. On the surface of these T-Reg cells, T-cell lung homing markers are expressed.
Investigational
PF-06882961
PF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).
Investigational
INCB-054329
Investigational
PF-04856884
PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination With Axitinib in Patients With Previously Treated Metastatic Renal Cell Carcinoma).
Investigational
MaaT013
MaaT013 is an allogeneic fecal microbiota therapy. It is being investigated for the treatment of Graft-Versus-Host Disease.
Investigational
Dimethyl Propionate Ester Heme
Experimental
Matched Iupac: … {2,6}.0^{16,23}.0^{18,22}.0^{11,25}]pentacosa-3(24),4,6,8,10,12,14,16,18,20-decaen-4-yl]propanoate ... methoxy-3-oxopropyl)-5,10,15,19-tetramethyl-2,22,23,25-tetraaza-1-ferraoctacyclo[11.9.1.1^{1,8}.1^{3,21}.0^ …
PF-00356231
Experimental
AN0128
AN0128 is a novel compound that contains a boron atom within a borinic acid complex. AN0128 has broad spectrum activity against a wide variety of Gram positive
bacteria, including many that are known skin colonizers. Of particular importance is P. acnes and its causal role in acne vulgaris. The rise...
Investigational
PN0621
PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.
Investigational
EP0057
EP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound camptothecin.
Investigational
Displaying drugs 1476 - 1500 of 1988 in total